Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry by Worni, Mathias et al.
ORIGINAL ARTICLE – HEPATOBILIARY TUMORS
Adjuvant Radiotherapy in the Treatment of Invasive Intraductal
Papillary Mucinous Neoplasm of the Pancreas: an Analysis
of the Surveillance, Epidemiology, and End Results Registry
Mathias Worni, MD1,2, Igor Akushevich, PhD3, Beat Gloor, MD2, John Scarborough, MD4, Junzo P. Chino, MD5,
Danny O. Jacobs, MD, MPH4, Stephen M. Hahn, MD6, Bryan M. Clary, MD4, Ricardo Pietrobon, MD, PhD, MBA1,
and Anand Shah, MD, MPH6
1Research on Research, Department of Surgery, Duke University Medical Center, Durham, NC; 2Department of Visceral
Surgery and Medicine, University of Bern, Bern, Switzerland; 3Center for Population Health and Aging, Duke University,
Durham, NC; 4Department of Surgery, Duke University Medical Center, Durham, NC; 5Department of Radiation
Oncology, Duke University Medical Center, Durham, NC; 6Department of Radiation Oncology, Hospital of the University
of Pennsylvania, Philadelphia, PA
ABSTRACT
Background. Management and outcomes of patients with
invasive intraductal papillary mucinous neoplasm (IPMN)
of the pancreas are not well established. We investigated
whether adjuvant radiotherapy (RT) improved cancer-spe-
cific survival (CSS) and overall survival (OS) among
patients undergoing surgical resection for invasive IPMN.
Methods. The Surveillance, Epidemiology, and End
Results (SEER) registry was used in this retrospective
cohort study. All adult patients with resection of invasive
IPMN from 1988 to 2007 were included. CSS and OS were
analyzed using Kaplan–Meier curves. Unadjusted and
propensity-score-adjusted Cox proportional-hazards mod-
eling were used for subgroup analyses.
Results. 972 patients were included. Adjuvant RT was
administered to 31.8% (n = 309) of patients. There was no
difference in overall median CSS or OS in patients who
received adjuvant RT (5-year CSS: 26.5 months; 5-year
OS: 23.5 months) versus those who did not (CSS:
28.5 months, P = 0.17; OS: 23.5 months, P = 0.23).
Univariate predictors of survival were lymph node (LN)
involvement, T4-classified tumors, and poorly differenti-
ated tumor grade (all P \ 0.05). In the propensity-score-
adjusted analysis, adjuvant RT was associated with
improved 5-year CSS [hazard ratio (HR): 0.67, P = 0.004]
and 5-year OS (HR: 0.73, P = 0.014) among all patients
with LN involvement, though further analysis by T-clas-
sification demonstrated no survival differences among
patients with T1/T2 disease; patients with T3/T4-classified
tumors had improved CSS (HR: 0.71, P = 0.022) but no
difference in OS (HR: 0.76, P = 0.06).
Conclusion. On propensity-score-adjusted analysis, adju-
vant RT was associated with improved survival in selected
subsets of patients with invasive IPMN, particularly those
with T3/T4 tumors and LN involvement.
The prevalence of invasive intraductal papillary
mucinous neoplasm (IPMN) has been estimated to be
approximately 26/100,000.1 In a national series of nearly
20,000 patients with pancreatic cancer, 95% had sporadic
adenocarcinoma whereas 5% patients had invasive IPMN.2
The World Health Organization (WHO) defines IPMN as
an intraductal mucin-producing lesion that contains tall,
columnar mucin-containing epithelium communicating
with pancreatic ducts.3,4 Absence of ovarian stroma in
IPMN distinguishes it from other mucin-producing cystic
neoplasms of the pancreas, such as mucinous cystadenoma
and cystadenocarcinoma.3,4 Although IPMN is a well-
characterized pancreatic neoplasm, the optimal strategy for
definitive treatment, especially the role of adjuvant radio-
therapy (RT) after surgical resection, is still debatable.
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Resection of noninvasive IPMN is associated with
favorable prognosis, whereas invasive IPMN has much
poorer outcome.5–11 Unfortunately, approximately 25% of
all resected IPMNs are invasive.12 Malignant transforma-
tion of IPMN from adenomatous stage to noninvasive and
subsequently invasive IPMN is similar to the development
of pancreatic ductal adenocarcinoma from pancreatic
intraepithelial neoplasia, though, unlike pancreatic adeno-
carcinoma, the natural history of invasive IPMN remains
poorly defined.13,14 Recent evidence suggests that invasive
IPMN in the setting of lymph node involvement, advanced
tumor stage and grade, tumor size [2 cm, and positive
resection margins is associated with poor outcomes com-
parable to pancreatic adenocarcinoma.15,16
Adjuvant chemoradiotherapy has been recommended for
many patients with pancreatic adenocarcinoma due to a
survival advantage compared with treatment with surgical
resection alone, though results from the European Study
Group for Pancreatic Cancer (ESPAC) ESPAC-1 trial
suggested that adjuvant RT may not be of benefit.17–23
However, the role of adjuvant RT in the treatment of
invasive IPMN has not been well studied. In a recent ret-
rospective series of 98 patients with invasive IPMN,
adjuvant chemoradiotherapy was not associated with a
survival benefit. It is difficult to draw conclusions from this
study, however, as it was limited by small sample size; only
37 patients received adjuvant chemotherapy or chemora-
diation.12 Using the population-based Surveillance,
Epidemiology, and End Results (SEER) cancer registry, we
thus tested the hypothesis that adjuvant RT in patients with
invasive IPMN of the pancreas following surgical resection
was associated with improved CSS and OS. In addition, we
performed propensity-score-adjusted analyses to account
for the nonrandomized allocation of patients receiving
adjuvant RT. Given the low prevalence of invasive IPMN,
prospective comparative trials are unlikely to be performed,
and small retrospective series are limited in the quality of
evidence. We felt, therefore, that a population-based study
using SEER and advanced statistical analyses using pro-
pensity-scoring methods had the potential to provide the
highest level of evidence possible for guiding therapy.
METHODS
We obtained Institutional Review Board approval for
this study. We conducted a secondary data analysis of
SEER, the largest, population-based cancer registry in the
USA. Patient data in SEER are currently collected pro-
spectively in 17 different geographic regions and represent
28% of the US population. In 2007, more than 350,000
cancer cases were recorded.24,25 We restricted our analysis
to a 20-year time period spanning from 1988 to 2007.
We used SEER*Stat 6.6.2 to extract IPMN cases from
the SEER registry.26 We primarily identified our patient
cohort through the ‘‘SEER Site Recode’’ using the term
‘‘pancreas.’’ Patients with IPMN were then identified using
the variable ‘‘Histologic Type ICD-O-3’’ (International
Classifications of Diseases for Oncology, 3rd edition) with
the following codes for IPMN: 8050, 8260, 8450, 8453,
8471, 8480, 8481, and 8503 and the label ‘‘malignant.’’2,16
We only included patients aged 18 years or older who
underwent surgical resection of invasive IPMN. We then
identified all patients who did or did not receive postop-
erative adjuvant external-beam RT. Patients undergoing
neoadjuvant (with or without adjuvant RT), intraoperative,
or unknown RT were excluded.
The primary outcome was 5-year survival measured in
months. The last available date in SEER for all patients
was collected. Patients alive at this time point were right-
censored in the survival analysis. The primary predictor in
our analysis was provision of postoperative external-beam
RT. To evaluate the effect of postoperative RT for different
patient groups, we performed subgroup analyses according
to available demographic variables in addition to charac-
teristics describing the extent and grade of the resected
tumor. Though tumor–node–metastasis (TNM) stage
according to AJCC for pancreatic cancer is not provided in
SEER for every year of our analysis, it is, in most cases,
possible to recode the AJCC stage manually using SEER
variables regarding the extent of disease.27,28 We added
a combined T1/T2 primary tumor classification group,
since 32 patients with\T3 disease had missing tumor size
and thus could not be more accurately categorized as being
either T1 or T2.
Available demographic characteristics including age,
sex, race, marital status, and presence of a single reportable
tumor were collected for all patients. Additionally, tumor
characteristics were included in the analysis: tumor loca-
tion (head of pancreas versus other location), primary
tumor (T1–T4, T1/T2, missing), regional lymph node sta-
tus (N0, N1, unknown), distant metastasis status (M0, M1,
unknown), tumor stage (stage 1–4, unknown), and tumor
size (\2 cm, C2 cm, unknown). In the SEER registry,
tumor size represents the size of the primary tumor and is
typically the largest known dimension or diameter of the
tumor (e.g., from pathology or operative reports) prior to
adjuvant therapy. Only the invasive component of the
IPMN is recorded in SEER; data regarding cystic compo-
nents, IPMN adenomas, or in situ carcinoma are
unavailable.25 To account for variation in measurement
techniques, we dichotomized tumor size (\2 cm versus
C2 cm) in our analysis. Data regarding classification of
IPMN as main duct, branch duct, or mixed type were
unavailable in SEER. The type of surgical procedure was
grouped into four categories: partial/localized resection,
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total pancreatectomy, pancreatoduodenectomy (Whipple
procedure), and all others.
Statistical Analysis
EmpiricAnalysisandKaplan–MeierEstimates Demographic
and tumor-related characteristics were compared according
to the provision of adjuvant RT using t-test for continuous
data and chi-square test for categorical data. Since our
primary objective is to evaluate the role of adjuvant RT, we
left-censored patients who survived less than 3 months after
diagnosis. The rationale for this censoring is that it mitigates
the potential for selection bias resulting from inclusion of
patients with adverse short-term perioperative outcomes and
also those who did not survive long enough to complete a
therapeutic regimen of RT.21,29 Patients with cause of death
other than pancreatic etiology were right-censored for the
CSS analysis to obtain specific estimates of pancreatic-
disease-related survival.30 We restricted the analysis to a
5-year survival period. Unadjusted survival analyses were
performed according to the method of Kaplan and Meier.
The resulting survival curves were compared using the log-
rank test. In addition, unadjusted Cox proportional-hazard
models were performed to obtain unadjusted hazard ratios
(HR) with corresponding confidence intervals for the entire
patient population as well as for important subgroups.
Estimates for grade 4 tumors were not calculated, since none
of these patients received RT.
Propensity Score Creation/Adjusted Survival Analysis Since
the focus of our study is establishing a causal inference
regarding the association between adjuvant RT and patient
outcomes, we used a propensity score methodology.
Propensity scores calculate the conditional probability of
receiving a treatment (e.g., adjuvant RT) given all potential
confounders measured. In providing such adjustments,
propensity scores approximate the results of nonrandom-
ized studies to their randomized counterparts.31 The
selection of variables for our study included in the
propensity score calculation was based on the potential
association with CSS and OS as well as on the likelihood of
receipt of adjuvant RT.32 These variables were chosen prior
to estimating survival. We included the following variables
in the propensity score calculation: year of operation, age,
sex, marital status, race, tumor location, tumor size, tumor
grade, presence of single reportable tumor, type of surgery,
primary tumor classification, regional lymph node status,
and presence of distant metastasis. The propensity score was
calculated through a multivariate logistic regression model
using the provision of adjuvant RT as the dependent variable
and the listed confounders as independent variables. The
propensity score was then used to perform survival analysis
using Cox proportional-hazard models and the technique of
stratification over the propensity score. HR and 95%
confidence intervals were calculated for all estimates.
Sensitivity Analyses We performed two sets of sensitivity
analyses. First, we performed the propensity-score-adjusted
survival analysis using Cox proportional-hazard models
without left-censoring of the first 3 months. Second, due to
the relatively high proportion of patients with distant
metastases who did not receive adjuvant RT (24.4%, versus
6.8% who did receive adjuvant RT), we repeated the
analyses excluding from both comparison groups patients
with distant metastases.
SAS software (version 9.2; SAS Institute, Cary, NC,
USA) was used for all analyses.
RESULTS
A total of 972 patients with invasive IPMN of the
pancreas were included in our analysis, of whom 476
(49.0%) were female (Table 1). The mean age of our
patient cohort was 64.9 years (range 18–94 years). Most
patients (n = 821, 84.5%) were White, while 74 (7.6%)
were Black and 77 (7.9%) were of indeterminate race/
ethnicity. Postoperative adjuvant RT was administered to
309 (31.8%) patients. Median follow-up for patients
undergoing adjuvant RT was 18 months (range: 0–180
months) versus 12 months (range: 0–213 months) in
patients not receiving adjuvant RT. More tumors were
located in the head of the pancreas in patients receiving
adjuvant RT compared with in those who did not receive
RT (70.6% versus 54.4%, P \ 0.001). The TNM tumor
characteristics were different between the two groups:
adjuvant RT was more commonly administered to patients
with T3 tumors (59.9%, versus 37.1% in patients with no
adjuvant RT, P \ 0.001), lymph node involvement (58.6%
versus 38.0%, P \ 0.001), and in the absence of metastatic
disease (92.6% versus 74.2%, P = 0.003). Univariate
predictors of survival were lymph node involvement, T4-
classified tumors, and poorly differentiated tumor grade (all
P \ 0.05).
Median OS of all patients without left-censoring for inva-
sive IPMN of the pancreas was 19.5 months (CI: 16.5–21.5
months) with a 5-year OS rate of 24.1% (CI: 21.1–27.3%).
After left-censoring the first 3 months of follow-up as descri-
bed earlier, the median OS of all patients was 23.5 months (CI:
21.5–26.5 months). The median OS for patients who received
adjuvant RT was 23.5 months (CI: 20.5–26.5 months), which
was similar compared with patients without adjuvant RT
(23.5 months, CI: 19.5–27.5 months, P = 0.23). The median
CSS for patients who received adjuvant RT was 26.5 months
(CI: 22.5–29.5 months) compared with 28.5 months (CI:
23.5–36.5 months) for patients who did not receive adjuvant
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RT (P = 0.17). Cause of death was similarly distributed
between the two groups (P = 0.16).
In subgroup analyses of CSS comparing patients who
received versus did not receive adjuvant RT, there was a
significant unadjusted survival benefit in patients with
lymph-node-positive disease [median survival: 21 (CI:
16–26) versus 12 (CI: 10–15) months, respectively,
P \ 0.001; Fig. 1], T4-classified tumors [median survival:
16 (CI: 10–25) versus 7 (CI: 6–9) months, P = 0.012],
and poorly differentiated tumors [median survival: 15 (CI:
12–28) versus 12 (CI: 10–15) months, P = 0.022]. In
addition, patients who received adjuvant RT with T3 or
TABLE 1 Demographics of patients with invasive IPMN of the
pancreas (1988–2007)
Adjuvant RT
(n = 309,
31.8%)
No adjuvant RT
(n = 663,
68.2%)
P-Value
Age (mean, SD), years 62.9 (11.2) 65.8 (12.8) 0.001
Female (n, %) 135 (43.7) 341 (51.4) 0.025
Race 0.92
White 262 (84.8) 559 (84.3)
Black 22 (7.1) 52 (7.8)
Others/unknown 25 (8.1) 52 (7.8)
Marital status 0.073
Married 213 (68.9) 418 (63.0)
Other 96 (31.1) 245 (37.0)
Tumor location \0.001
Head of pancreas 218 (70.6) 361 (54.4)
Other 91 (29.4) 302 (45.6)
Primary tumor (T) \0.001
T1 14 (4.5) 63 (9.5)
T2 49 (15.9) 145 (21.9)
T3 185 (59.9) 246 (37.1)
T4 51 (16.5) 163 (24.6)
Unknown 3 (1.0) 21 (3.2)
T1/T2 7 (2.3) 25 (3.8)
Regional lymph nodes (N) \0.001
N0 118 (38.2) 364 (54.9)
N1 181 (58.6) 252 (38.0)
Unknown 10 (3.2) 47 (7.1)
Distant metastasis (M) \0.001
M0 286 (92.6) 492 (74.2)
M1 21 (6.8) 162 (24.4)
Unknown 2 (0.6) 9 (1.4)
Stage \0.001
Stage 1 39 (12.6) 177 (26.7)
Stage 2 210 (68.0) 279 (42.1)
Stage 3 36 (11.7) 24 (3.6)
Stage 4 21 (6.8) 162 (24.4)
Unknown 3 (1.0) 21 (3.2)
Tumor grade 0.001
G1 (well) 58 (18.8) 120 (18.1)
G2 (moderate) 128 (41.4) 223 (33.6)
G3 (poor) 67 (21.7) 111 (16.7)
G4 (undifferentiated) 0 11 (1.7)
Unknown 56 (18.1) 198 (29.9)
Tumor size \0.001
\2 cm 45 (14.6) 99 (14.9)
C2 cm 228 (73.8) 396 (59.7)
Unknown 36 (11.7) 168 (25.3)
Single reportable tumor
(n, %)
254 (82.2) 538 (81.1) 0.69
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FIG. 1 Kaplan–Meier curves comparing CSS (straight lines,
P \ 0.001) and OS (dotted lines, P \ 0.001) for patients with
lymph-node-positive (N1) invasive IPMN who received adjuvant RT
versus those who did not. In the first 3 months, 4 patients were left-
censored in the RT group and 61 were left-censored in the non-RT
group
TABLE 1 continued
Adjuvant RT
(n = 309,
31.8%)
No adjuvant RT
(n = 663,
68.2%)
P-Value
Type of surgery \0.001
Partial/localized 38 (12.3) 101 (15.2)
Total pancreatectomy 25 (8.1) 69 (10.4)
Pancreatoduodenectomy 230 (74.4) 380 (57.3)
Other 16 (5.2) 113 (17.0)
Cause of death 0.16
Alive 83 (26.9) 198 (29.9)
Pancreas 192 (62.1) 371 (56.0)
Other cause of death 34 (11.0) 94 (14.2)
Values are counts and % if not otherwise indicated
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TABLE 2 Effect of adjuvant RT on 5-year CSS and OS calculated using unadjusted and propensity-score-adjusted stratified multivariate Cox
proportional-hazard modeling
Cancer-specific survival (CSS) Overall survival (OS)
Unadjusted Adjusted Unadjusted Adjusted
HR (95% CI) P-Value HR (95% CI) P-Value HR (95% CI) P-Value HR (95% CI) P-Value
Overall 0.95 (0.79–1.14) 0.56 0.92 (0.75–1.14) 0.43 1.11 (0.93–1.33) 0.24 1.00 (0.82–1.22) 0.96
Age
\65 years 1.25 (0.95–1.66) 0.11 0.87 (0.63–1.20) 0.38 1.21 (0.93–1.58) 0.15 0.86 (0.63–1.16) 0.30
C65 years 1.07 (0.82–1.39) 0.60 0.94 (0.70–1.26) 0.66 1.06 (0.84–1.35) 0.60 0.99 (0.75–1.29) 0.92
Sex
Female 1.24 (0.94–1.63) 0.12 0.88 (0.64–1.23) 0.45 1.22 (0.95–1.58) 0.12 0.90 (0.68–1.19) 0.46
Male 1.07 (0.82–1.40) 0.62 0.92 (0.68–1.24) 0.58 1.03 (0.80–1.32) 0.82 0.98 (0.72–1.33) 0.88
Race
White 1.13 (0.92–1.38) 0.24 0.95 (0.75–1.20) 0.66 1.09 (0.90–1.31) 0.39 0.96 (0.77–1.18) 0.67
Black 0.92 (0.45–1.89) 0.82 0.56 (0.18–1.79) 0.32 0.92 (0.47–1.78) 0.80 0.60 (0.22–1.68) 0.32
Marital status
Married 1.10 (0.79–1.53) 0.22 0.99 (0.77–1.28) 0.94 1.17 (0.94–1.46) 0.15 1.01 (0.80–1.29) 0.92
Other 1.15 (0.91–1.46) 0.57 0.77 (0.51–1.17) 0.22 1.01 (0.75–1.36) 0.95 0.86 (0.59–1.25) 0.42
Tumor location
Head of pancreas 1.00 (0.79–1.27) 0.98 0.79 (0.60–1.02) 0.06 1.02 (0.82–1.27) 0.87 0.82 (0.64–1.05) 0.11
Other 1.40 (1.01–1.96) 0.042 1.45 (0.99–2.14) 0.05 1.32 (0.98–1.79) 0.064 1.36 (0.97–1.92) 0.073
Primary tumor (T)
T1 2.10 (0.70–6.27) 0.18 1.17 (0.35–3.97) 0.80 1.80 (0.68–4.77) 0.23 1.21 (0.40–3.73) 0.73
T2 1.47 (0.85–2.52) 0.16 1.16 (0.63–2.12) 0.63 1.32 (0.81–2.16) 0.25 1.08 (0.62–1.87) 0.78
T3 1.01 (0.77–1.31) 0.96 0.85 (0.63–1.14) 0.26 1.02 (0.79–1.30) 0.90 0.89 (0.68–1.18) 0.41
T4 0.64 (0.43–0.93) 0.017 0.75 (0.44–1.27) 0.27 0.63 (0.44–0.91) 0.01 0.72 (0.43–1.23) 0.22
T1/T2 1.62 (1.00–2.63) 0.048 1.11 (0.67–1.87) 0.67 1.45 (0.94–2.24) 0.09 1.10 (0.69–1.76) 0.69
T3/T4 0.81 (0.65–1.00) 0.049 0.87 (0.69–1.11) 0.25 0.82 (0.67–1.01) 0.05 0.92 (0.73–1.15) 0.46
Regional lymph nodes (N)
N0 1.50 (1.09–2.07) 0.012 1.35 (0.95–1.91) 0.089 1.38 (1.03–1.85) 0.029 1.26 (0.92–1.74) 0.14
N1 0.59 (0.46–0.76) \0.001 0.67 (0.51–0.89) 0.004 0.63 (0.50–0.81) \0.001 0.73 (0.56–0.94) 0.014
Distant metastasis (M)
M0 1.43 (1.16–1.78) 0.001 0.91 (0.72–1.15) 0.42 1.39 (1.14–1.69) 0.001 0.94 (0.76–1.18) 0.61
M1 0.80 (0.47–1.34) 0.38 0.62 (0.33–1.18) 0.14 0.76 (0.46–1.25) 0.27 0.60 (0.32–1.10) 0.091
Tumor grade
G1 (well) 1.94 (1.19–3.17) 0.007 1.55 (0.87–2.75) 0.13 1.78 (1.13–2.79) 0.011 1.54 (0.90–2.64) 0.11
G2 (moderate) 1.01 (0.75–1.36) 0.96 0.88 (0.60–1.27) 0.47 1.03 (0.78–1.37) 0.81 0.91 (0.64–1.29) 0.59
G3 (poor) 0.63 (0.42–0.96) 0.027 0.74 (0.47–1.18) 0.20 0.67 (0.46–0.98) 0.035 0.79 (0.51–1.22) 0.28
T-classification T1/T2
N0 1.64 (0.82–3.30) 0.16 1.28 (0.60–2.76) 0.51 1.25 (0.65–2.39) 0.49 1.19 (0.59–2.43) 0.62
N1 0.73 (0.36–1.47) 0.37 0.78 (0.34–1.79) 0.55 0.86 (0.46–1.63) 0.64 0.73 (0.32–1.64) 0.43
T-classification T3/T4
N0 1.09 (0.75–1.59) 0.64 1.22 (0.78–1.91) 0.37 1.08 (0.76–1.52) 0.68 1.25 (0.82–1.88) 0.29
N1 0.57 (0.43–0.75) \0.001 0.71 (0.52–0.96) 0.022 0.61 (0.47–0.79) \0.001 0.76 (0.56–1.02) 0.06
The reference group is those patients who did not receive adjuvant RT. Propensity score calculation based on: year of operation, age, sex, marital
status, race, tumor location, tumor size, tumor grade, single reportable tumor, type of surgery, primary tumor (T), regional lymph nodes (N), and
distant metastasis (M)
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T4 tumors and positive lymph nodes demonstrated a
median CSS of 20 months (CI: 15–25 months) compared
with 12 months (CI: 10–14 months, P \ 0.001) for
patients not receiving adjuvant RT (Fig. 2).
Given the above findings, we performed Cox propor-
tional-hazard model analysis stratified over propensity
score to account for nonrandomized provision of adjuvant
RT. We compared outcomes for patients who received
versus did not receive adjuvant RT. There was no overall
CSS or OS difference after propensity score adjustment
(Table 2). In subgroup analyses, patients with lymph node
involvement who received adjuvant RT demonstrated
improved CSS (HR: 0.67, CI: 0.51–0.89, P = 0.004) and
OS (HR: 0.73, CI: 0.56–0.94, P = 0.014). In patients with
T3/T4-classified tumors with lymph node positivity, adju-
vant RT was associated with improved CSS (HR: 0.71, CI:
0.52–0.96, P = 0.022), though there was no difference in
OS (HR: 0.76, CI: 0.56–1.02, P = 0.06). There was no
survival difference among patients with T1/T2 tumors and
positive lymph nodes. There was no significant difference
in CSS or OS in patients with negative lymph nodes. All
other subgroup analyses demonstrated no statistically sig-
nificant differences. Unadjusted and adjusted HR for CSS
and OS are presented in Table 2.
When the analysis was performed without left-censor-
ing, there were no significant changes compared with the
primary analysis. Furthermore, excluding patients with
distant metastasis in the propensity-score-adjusted analyses
also did not significantly change the results of the primary
analysis [CSS (HR: 0.61, CI: 0.45–0.82, P \ 0.001) and
OS (HR: 0.67, CI: 0.50–0.89, P = 0.005) comparing
patients with lymph-node-positive disease who received
versus did not receive RT], though patients with T3/T4-
classified tumors and positive lymph nodes had improved
CSS and, additionally, an OS benefit with adjuvant RT
(HR: 0.58, CI: 0.41–0.82, P = 0.001 and HR: 0.65, CI:
0.47–0.91, P = 0.009, respectively).
DISCUSSION
IPMN has potential for malignant transformation to
pancreatic adenocarcinoma, but, unlike pancreatic adeno-
carcinoma, the role of adjuvant therapy is not well studied.
In this retrospective cohort study of the SEER cancer
registry from 1998 to 2007, we examined whether adjuvant
RT following surgical resection was associated with a
survival benefit compared with no adjuvant RT. We used
SEER to address sample size limitations of prior studies
and to examine subgroup differences in survival out-
comes.6,9,12,33 Our findings demonstrate a significant
survival benefit in patients with lymph-node-positive
invasive IPMN who received adjuvant RT, though further
analysis suggests this benefit is limited to those patients
with T3/4 tumors. As with pancreatic adenocarcinoma,
adjuvant RT may have an important role in treatment of
invasive IPMN, especially in selected patients with lymph-
node-positive disease.34,35
IPMN accounts for nearly 5% of all resected malignant
pancreatic neoplasms, but there is a paucity of data
investigating the role of adjuvant therapy in patients with
invasive IPMN.2 Many patients presently receive adjuvant
therapy based on clinical evidence generated for treatment
of pancreatic ductal adenocarcinoma. An emerging body of
evidence suggests that IPMN and pancreatic adenocarci-
noma, in fact, have a different natural history and
prognosis.6,9,10,15,16,36–39 Most studies to date of adjuvant
RT have been single-center and pooled multisite series of
adjuvant chemotherapy (with or without RT) in a limited
number of patients with invasive pancreatic IPMN.6,9,12
Using SEER, we were able to identify a large cohort of
cases and, accordingly, achieve sufficient statistical power
to estimate subgroup differences according to provision of
adjuvant RT. In this nonrandomized observational dataset,
we used propensity-score-adjusted analysis to mitigate the
effects of confounders.
Patients with invasive IPMN have poor prognosis: the
5-year OS is estimated to be 22–46%.6,7,9,10,12,15,16,33,37,38
In our population-based study of 972 patients, the 5-year
OS for patients with and without adjuvant RT was 24%,
which is on the lower end of previously reported survival.
Our findings, however, suggest that certain subgroups may
benefit from RT following surgical resection. Lymph node
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FIG. 2 Kaplan–Meier curves comparing CSS (straight lines,
P \ 0.001) and OS (dotted lines, P \ 0.001) for patients with T3/
T4, lymph-node-positive (N1), invasive IPMN who received adjuvant
RT versus those who did not. In the first 3 months, 3 patients were
left-censored in the RT group and 51 were left-censored in the non-
RT group
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involvement was highly predictive of worsened survival:
the 5-year OS for lymph-node-positive invasive IPMN in
the present study was 12% (published range: 0–45%)
compared with 42% for patients with node-negative tumors
(40–85%).5–9,12,36 The difference in OS between patients
with versus without lymph node involvement is consistent
with previous reports.
In the present study, the survival benefit associated with
adjuvant RT was limited to patients with positive regional
lymph nodes, though further analyses suggested this was
limited to patients with advanced T stage (T3/T4) and
positive regional lymph nodes. It is likely that patients with
such tumors have higher probability of positive resection
margins and/or residual positive lymph nodes, and are thus
more likely to benefit from adjuvant RT. It should be noted,
however, that the SEER registry does not contain infor-
mation regarding surgical margin status, thus limiting our
conclusions.
We acknowledge several other potential limitations of
the present study. First, retrospective secondary data
analyses are impacted by selection bias. Propensity score
adjustment is one means to mitigate such bias. Nonethe-
less, propensity score adjustment itself can only take into
account what is explicitly known through the SEER reg-
istry. The propensity score calculation thus lacks several
patient (e.g., body mass index, comorbidities), tumor (e.g.,
resection margin), and hospital characteristics (e.g., hos-
pital volume) that are unavailable in SEER but which
potentially influence both survival as well as the proba-
bility of receiving adjuvant RT. Second, data regarding the
details of external-beam RT (e.g., technique, dose) are not
available in SEER. Third, data regarding adjuvant che-
motherapy administration are unavailable in the SEER
registry. We are therefore unable to identify patients who
may have also received adjuvant chemotherapy. No
guidelines presently exist for adjuvant therapy for invasive
IPMN; it is likely that many therapeutic regimens include a
combined approach using adjuvant chemoradiotherapy.
This is supported by Turrini et al., who did not report any
patients receiving adjuvant RT alone in a retrospective
analysis of two major centers in the USA.12 Fourth, the
identification of invasive IPMN in the SEER registry is
based on ICD-O-3 codes. The nature of administrative, de-
identified databases does not allow for verification of coded
pathological diagnoses. Though unlikely, we acknowledge
the possibility of misclassification of these tumors. Lastly,
p-values approaching 0.05 should be interpreted with
caution due to multiple testing related to the subgroup
analyses.
In essence, the results from our study demonstrate that,
in the setting of lymph-node-positive disease and advanced
T stage, adjuvant RT in patients with invasive IPMN is
associated with an improvement in 5-year CSS. Further
studies are needed to investigate the role of adjuvant
therapy in the treatment of invasive IPMN, particularly the
role of single-modality and combined chemoradiotherapy
approaches. Nevertheless, the suggested benefit of adjuvant
RT in select patients with invasive IPMN is encouraging.
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